Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	22.99B +8.7%
Revenue (ttm)	6.02B +8.9%
Net Income	1.23B +5.0%
EPS	1.21 +4.3%
Shares Out	1.02B
PE Ratio	18.69
Forward PE	18.25
Dividend	0.36 (1.58%)
Ex-Dividend Date	May 14, 2025

Volume	6,635,771
Average Volume	6,176,449
Open	22.50
Previous Close	22.73
Day's Range	22.39 - 22.80
52-Week Range	20.36 - 29.30
Beta	-0.27
RSI	38.75
Earnings Date	Apr 18, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,923
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.